Adaptive Biotechnologies Corporation (ADPT) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2021)
ADPT's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
ADPT Revenue Analysis (2017–2024)
As of March 5, 2026, Adaptive Biotechnologies Corporation (ADPT) generated trailing twelve-month (TTM) revenue of $252.8 million, reflecting explosive growth of +102.4% year-over-year. The most recent quarter (Q3 2025) recorded $94.0 million in revenue, up 59.6% sequentially.
Looking at the longer-term picture, ADPT's 5-year compound annual growth rate (CAGR) stands at +16.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $185.3 million in 2022.
Revenue diversification analysis shows ADPT's business is primarily driven by Sequencing Revenue (51%), Development Support Revenue (42%), and Development Revenue Regulatory Milestones (6%). With over half of revenue concentrated in Sequencing Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CAI (+144.9% YoY), VCYT (+16.0% YoY), and CDIO (-55.8% YoY), ADPT has underperformed the peer group in terms of revenue growth. Compare ADPT vs CAI →
Peer Comparison
Compare ADPT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADPTCurrent | $253M | +102.4% | +16.0% | -90.8% | |
 CAI | $812M | +144.9% | +14.3% | 5.6% | |
 VCYT | $517M | +16.0% | +34.5% | 11.2% | |
 CDIO | $34,890 | -55.8% | - | -23977.9% | |
 SEER | $14M | +14.5% | +160.6% | -717.7% | |
 IMDX | $2M | +520.9% | - | -3245.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $179.0M | +5.1% | $106.9M | 59.7% | $-162,549,000 | -90.8% |
| 2023 | $170.3M | -8.1% | $94.7M | 55.6% | $-227,035,000 | -133.3% |
| 2022 | $185.3M | +20.1% | $127.4M | 68.7% | $-200,186,000 | -108.0% |
| 2021 | $154.3M | +56.9% | $105.0M | 68.1% | $-208,966,000 | -135.4% |
| 2020 | $98.4M | +15.6% | $75.9M | 77.1% | $-152,817,000 | -155.3% |
| 2019 | $85.1M | +52.8% | $62.8M | 73.8% | $-78,391,000 | -92.1% |
| 2018 | $55.7M | +44.8% | $36.0M | 64.7% | $-49,756,000 | -89.4% |
| 2017 | $38.4M | - | $22.8M | 59.2% | $-44,475,000 | -115.7% |
See ADPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADPT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADPT vs LLY
See how ADPT stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is ADPT's revenue growth accelerating or slowing?
ADPT revenue is accelerating at +102.4% year-over-year, exceeding the 5-year CAGR of +16.0%. TTM revenue reached $253M. Growth momentum has increased versus prior periods.
What is ADPT's long-term revenue growth rate?
Adaptive Biotechnologies Corporation's 5-year revenue CAGR of +16.0% reflects the sustained expansion pattern. Current YoY growth of +102.4% is above this long-term average.
How is ADPT's revenue distributed by segment?
ADPT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.